Previous 10 | Next 10 |
2023-05-03 07:02:25 ET Amarin press release ( NASDAQ: AMRN ): Q1 Non-GAAP EPS of -$0.02 misses by $0.01 . Revenue of $85.7M (-9.4% Y/Y) beats by $4.47M . For further details see: Amarin Non-GAAP EPS of -$0.02 misses by $0.01, revenue of $85.7M beats by $4...
-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA ® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing -- ...
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President & CEO, and members of Amarin’s senior management team to discuss the Company’s f...
2023-04-17 07:11:02 ET Amarin ( NASDAQ: AMRN ) announced on Monday the appointment of Aaron Berg as interim president and CEO, effective immediately. Berg, who has more than 25 years of biopharmaceutical industry experience, currently serves as Amarin's executive vice pres...
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interim P...
2023-04-16 09:15:01 ET Summary Sarissa Capital has taken full control of Amarin. The previous management was doing some slow but decent work, but did not get time to show results. Sarissa hasn't disclosed material plans. In February, I wrote that while Amarin ( ...
2023-04-04 15:53:30 ET U.S. stock markets are under heavy pressure today after two reports on job openings and factory orders came in weaker than expected. The key issue at play is a growing concern that the Federal Reserve's rate hiking campaign may spark a deep and long-lasting economic d...
2023-04-04 08:35:01 ET Ireland-based biotech Amarin Corporation ( NASDAQ: AMRN ) added ~5% pre-market Tuesday after announcing that Israel’s Ministry of Health approved its fish oil-derived heart disease therapy Vazkepa (icosapent ethyl). Accordingly, Vazkepa will b...
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –- -- Heart Disease Second Leading Cause of Death in Men and Wome...
2023-03-31 09:18:55 ET Ireland-based biotech Amarin Corporation ( NASDAQ: AMRN ) announced Friday that President and Chief Executive Officer Karim Mikhail has decided to step down, effective immediately. Amarin ( AMRN ), the developer of fish oil-derived therapy Vascep...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...